Enliven Therapeutics, Inc.ELVNNASDAQ
Loading
Year-over-year operating cash flow growth rate
Percentile
P33
Within normal range
vs 5Y Ago
-1x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -19.27% |
| Q3 2025 | 22.15% |
| Q2 2025 | 29.30% |
| Q1 2025 | -40.25% |
| Q4 2024 | -41.09% |
| Q3 2024 | 40.33% |
| Q2 2024 | 12.53% |
| Q1 2024 | -87.16% |
| Q4 2023 | 21.47% |
| Q3 2023 | -31.91% |
| Q2 2023 | 42.19% |
| Q1 2023 | -1008.72% |
| Q4 2022 | 70.84% |
| Q3 2022 | 9.50% |
| Q2 2022 | 31.24% |
| Q1 2022 | 17.01% |
| Q4 2021 | -14.53% |
| Q3 2021 | -5.17% |
| Q2 2021 | 20.39% |
| Q1 2021 | -57.46% |
| Q4 2020 | 20.08% |
| Q3 2020 | -11.78% |
| Q2 2020 | 2.84% |
| Q1 2020 | -18.47% |
| Q4 2019 | -28.06% |
| Q3 2019 | -21.99% |
| Q2 2019 | -113.88% |
| Q1 2019 | 0.00% |